Xseer Pharmaceuticals, Inc.

The FDA's record of Xseer Pharmaceuticals, Inc. of Los Angeles, CA, a registered 503B outsourcing facility: its registration dates and its inspection record.

Checked against the FDA registered outsourcing facilities list on Oct 25, 2026. See the list on fda.gov

503B outsourcing facilityNot yet inspected

Xseer Pharmaceuticals, Inc. of Los Angeles, California is on the FDA’s list of facilities registered as human drug compounding outsourcing facilities under section 503B of the Federal Food, Drug, and Cosmetic Act. The FDA says the list includes the facilities whose registration information it has determined to be complete.1

The list shows no FDA inspection of this facility yet. The FDA says it adds each registered outsourcing facility to the facilities it intends to inspect on a risk-based schedule, and that the timing depends on several variables, including the facility’s operational status.1

The record

What the FDA register shows

Column	What the register shows	Source
Facility	Xseer Pharmaceuticals, Inc., Los Angeles, CA	FDA register
Initial registration date	Oct 21, 2023	FDA register
Most recent registration date	Dec 25, 2025	FDA register
Last inspection	Not yet inspected	FDA register
Form 483 issued?	N/A: not yet inspected	FDA register
Recall conducted?	N/A: not yet inspected	FDA register
Action based on last inspection	N/A: not yet inspected	FDA register
Intends to compound sterile drugs from bulk substances	Yes	Stated by the facility at registration; not verified by the FDA

How a 503B outsourcing facility differs from a 503A pharmacy: 503A vs 503B.

This page restates public FDA records as they stood on the check date above. It is not legal or medical advice.

503A vs 503B Pharmacies: What FDA's Inspection Record Shows

42 of 99 registered 503B outsourcing facilities have never been inspected

Data sources

1.
FDA registered outsourcing facilitiesU.S. Food and Drug Administrationretrieved Oct 25, 2026↩